# First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss

> **NCT05664100** · PHASE1 · TERMINATED · sponsor: **Frequency Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Hearing Loss, Sensorineural

## Interventions

- **DRUG:** FX-345
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05664100
- **Lead sponsor:** Frequency Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-15
- **Primary completion:** 2023-04-12
- **Final completion:** 2023-04-12
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2023-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05664100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05664100, "First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05664100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*